
    
      Patients: All consecutive patients with compensated HBV, HCV, alcohol or
      hemochromatosis-related cirrhosis (without any previous clinical complication including liver
      cancer).

      Randomization: factorial: ultrasonography (3-month versus 6-month); serum alfa-fetoprotein
      assay (none versus 6-month).

      End points: rate of small tumors (first main criteria); survival (second main criteria).
    
  